-
Mashup Score: 2
Serial testing of ctDNA could improve risk stratification for determining adjuvant treatment in patients with high-risk muscle-invasive bladder cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
The intravesical gene therapy elicited durable remissions in a high percentage of patients with high-risk, BCG-unresponsive non–muscle invasive bladder cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
Serial testing of ctDNA could improve risk stratification for determining adjuvant treatment in patients with high-risk muscle-invasive bladder cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
The intravesical gene therapy elicited durable remissions in a high percentage of patients with high-risk, BCG-unresponsive non–muscle invasive bladder cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
The intravesical gene therapy elicited durable remissions in a high percentage of patients with high-risk, BCG-unresponsive non–muscle invasive bladder cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
Serial testing of ctDNA could improve risk stratification for determining adjuvant treatment in patients with high-risk muscle-invasive bladder cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
The intravesical gene therapy elicited durable remissions in a high percentage of patients with high-risk, BCG-unresponsive non–muscle invasive bladder cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Investigators report 2-year rates of overall, recurrence-free, and progression-free survival for patients with NMIBC and MIBC in the Netherlands.
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 0Intravesical Durvalumab Feasible for High-Risk NMIBC After BCG Failure - Renal and Urology News - 1 month(s) ago
Intravesical durvalumab produced no serious adverse events in a small trial, suggesting a favorable toxicity profile.
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet
Serial ctDNA Testing Could Improve Risk Stratification in High-Risk MIBC @tompowles1 @NHSBartsHealth @Uroweb #EAU24 #blcsm https://t.co/GvEwUsEPZN